GlassScriptPhysician profile
John A A Dawdy
NPI 1144676669
$11,197.78
in general payments reported to CMS, 2019-2025
20 companies · $7,444 in 2025
The $7,444 reported for 2025 was more than what 93% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $31.05 · 2020: $66.78 · 2021: $656 · 2022: $445 · 2023: $437 · 2024: $2,118 · 2025: $7,444.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,300 · Travel and Lodging: $2,546 · Food and Beverage: $2,153.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,300.00 |
| Travel and Lodging | $2,545.79 |
| Food and Beverage | $2,153.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $9,084.29 | 2024-2025 | Evoque, Pascal, Sapien 3 Ultra Resilia |
| Amgen INC. | $378.32 | 2019-2024 | Repatha |
| Boston Scientific Corporation | $354.27 | 2020-2024 | Lux-Dx Insertable Cardiac Monitor, Emblem Mri S-Icd |
| Biotronik INC. | $255.07 | 2021 | |
| Pfizer INC. | $247.40 | 2021-2023 | |
| Lantheus Medical Imaging, INC. | $222.67 | 2020-2023 | Definity |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $159.28 | 2023-2025 | Lifevest |
| Medtronic, INC. | $121.98 | 2021-2023 | Linq II |
| Chiesi USA, INC. | $65.08 | 2022-2025 | Kengreal, Cleviprex |
| Abbott Laboratories | $60.25 | 2024-2025 | Triclip, Amplatzer Amulet |
| Philips North America LLC | $42.92 | 2024 | (O49) Image Guided Therapy Und |
| Sobi, INC | $36.76 | 2021 | |
| Itamar Medical INC | $33.57 | 2023 | Watchpatone |
| Astrazeneca Pharmaceuticals LP | $28.01 | 2022-2023 | Farxiga |
| E.R. Squibb & Sons, L.L.C. | $26.39 | 2023 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $18.93 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.49 | 2021 | |
| Terumo Medical Corporation | $15.92 | 2023 | Tr Band |
| Merck Sharp & Dohme LLC | $15.51 | 2021 | |
| Cordis US Corp. | $14.67 | 2024 | Mynx Venous Vcd |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Dawdy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.